JASON M. REEFER is a partner in the Product Liability Practice Group at Pietragallo Gordon Alfano Bosick & Raspanti, LLP.

Mr. Reefer’s practice is dedicated to defending manufacturers in litigation pending throughout the United States. He has particular expertise in cases involving pharmaceuticals, medical devices, automobiles, powersports equipment, and firearms. He has litigated at all levels of state and federal court, including the U.S. Supreme Court, where he represented an amicus curiae in the seminal case, Mutual Pharmaceutical Co. v. Bartlett.

As national and regional counsel to numerous publicly-traded companies, Mr. Reefer has extensive experience as liaison and lead counsel in federal multidistrict litigation and state mass-tort programs. His practice is truly national in scope, having handled cases from Bangor, Maine to San Diego, California and countless jurisdictions in between.

His expertise, however, extends well beyond the courtroom. Recognizing that litigation involving large-scale manufacturers is oftentimes inevitable, Mr. Reefer takes a proactive approach to understanding his client’s business interests and ensuring that a company takes all appropriate steps to prepare its defense before a complaint is ever filed. For that reason, he has assisted with the preparation and revision of product-safety manuals and on-product warnings and has counseled clients with regard to the implementation and completion of product recalls in accordance with CPSC and FDA guidelines.

He holds two degrees from the University of Pennsylvania: a B.A., summa cum laude, with Distinction; and a J.D., where he served as a Senior Editor of the Journal of Constitutional Law. Before joining Pietragallo, Mr. Reefer was an attorney at an Am Law 100 firm.

The following is a list of representative orders and opinions entered in cases handled by Mr. Reefer:

1. Mutual Pharm. Co. v. Bartlett, 568 U.S. 1045 (2012) (granting petition for writ of certiorari)
2. Hayes v. Smith & Wesson, 692 F. App’x 70 (2d Cir. 2017) (affirming summary judgment)
3. Smith v. Mylan Inc., 761 F.3d 1042 (9th Cir. 2014) (reversing remand order)
4. State, ex rel. Mylan, Inc. v. Zakaib, 713 S.E.2d 356 (W. Va. 2011) (granting petition for extraordinary writ)
5. State ex rel. Mylan Bertek Pharm., Inc. v. Vincent, 561 S.W.3d 68 (Mo. Ct. App. 2018) (granting petition for extraordinary writ)
6. Marroquin v. Pfizer, Inc., 367 F. Supp. 3d 1152 (E.D. Cal. 2019) (complete dismissal)
7. Watson v. Mylan Pharmaceuticals Inc., No. 5:18-cv-04137, 2019 WL 3252745 (D. Kan. July 18, 2019) (complete dismissal)
8. Coleson v. Mylan Pharm. Inc., No. 1:17-cv-5382, 2019 WL 2325776 (S.D.N.Y. May 30, 2019) (complete dismissal)
9. Sullivan v. Polaris Industries, Inc., No. 1:16-cv-2546, 2017 WL 4544619 (M.D. Pa. Sept. 29, 2017) (complete dismissal)
10. Elmazouni v. Mylan Inc., 220 F. Supp. 3d 736 (N.D. Tex. Dec. 1, 2016) (complete dismissal)
11. McNeal v. Smith & Wesson Corp., No. 3:16-cv-67, 2016 WL 4399354 (M.D. Tenn. Aug. 18, 2016) (complete dismissal)
12. Johnson v. Mylan Inc., 107 F. Supp. 3d 967 (E.D. Wisc. 2015) (complete summary judgment)
13. Dolin v. SmithKline Beecham Corp., 62 F. Supp. 3d 705 (N.D. Ill. 2014) (complete dismissal)
14. Ballard v. Johnson & Johnson, No. 4:14-cv-404, 2014 WL 5341851 (N.D. Okla. Oct. 20, 2014) (complete dismissal)
15. Manous v. Mylan Pharms. Inc., 982 F. Supp. 2d 1282 (W.D. Okla. 2013) (complete summary judgment)
16. In re Watson Fentanyl Patch Prod. Liab. Litig., 883 F. Supp. 2d 1350 (J.P.M.L. 2012) (successfully opposing motion to centralize)

Mr. Reefer participated in the following trials, each resulting in a defense verdict.

• Andrusis v. Microvention, No. GD 08-016008 (Pa. Com. Pl. 2017)
• Fraser v. Polaris Industries Inc., No. OCN-L-797-10 (N.J. Sup. Ct. 2013)
• Dolata v. Suzuki Motor Corp., No. GD 09-023225 (Pa. Com. Pl. 2014)
• Mardegan v. Mylan Inc., No 2:10-cv-14285 (S.D. Fla. 2012)
• Richardson v. Mylan Inc., No. 3:09-cv-1041 (S.D. Cal. 2010)